Key Takeaways Reliance on a narrow set of high-earning drugs and pipeline uncertainty increases exposure to competitive threats and potential revenue volatility. Ongoing price pressures, biosimilar competition, and major capital investments risk squeezing margins, straining cash flow, and impacting long-term growth prospects.Read more
Key Takeaways Robust drug pipeline management and advanced manufacturing scale position Chugai to outpace rivals in innovation, output, and profitability as global biologic demand rises. Strategic investments in AI-driven discovery and portfolio focus enhance R&D productivity, enabling strong market leadership in next-generation, high-margin therapies.Read more
Key Takeaways Focus on biologics, personalized medicine, and R&D productivity positions Chugai well for future growth and expansion of high-value therapies. Strategic partnerships, supply chain investments, and innovation improve global reach, production efficiency, and profit potential.Read more
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.